FDA Advisory Committee Splits on COPD Indication for GlaxoSmithKline Drug

An advisory panel Wednesday recommended that the FDA collect more data before signing off on use of GlaxoSmithKline’s asthma drug mepolizumab for treating chronic obstructive pulmonary disease (COPD).
Source: Drug Industry Daily